{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:40:11Z","timestamp":1751690411009,"version":"3.41.0"},"reference-count":38,"publisher":"Center for Academic Publications Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nutr Sci Vitaminol","JNSV","Journal of Nutritional Science and Vitaminology, J Nutr Sci Vitaminol","Journal of Nutritional Science and Vitaminology"],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.3177\/jnsv.71.256","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T22:08:52Z","timestamp":1751234932000},"page":"256-266","source":"Crossref","is-referenced-by-count":0,"title":["<i>Cephalotaxus harringtonia<\/i> and Their Constituents Harringtonine Alkaloids Inhibit FoxO1 and 3a Activity and Atrophy-Related Gene Expression in C2C12 Myotubes"],"prefix":"10.3177","volume":"71","author":[{"given":"Manami","family":"KATO","sequence":"first","affiliation":[{"name":"Laboratory of Nutritional Biochemistry, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"SATO","sequence":"additional","affiliation":[{"name":"Laboratory of Nutritional Biochemistry, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"FUCHINO","sequence":"additional","affiliation":[{"name":"Tsukuba Division, Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"KAWAKAMI","sequence":"additional","affiliation":[{"name":"Tsukuba Division, Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"YOSHIMATSU","sequence":"additional","affiliation":[{"name":"Tsukuba Division, Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"IIJIMA","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shino","family":"HIRAOKA","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"TANG","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"MANABE","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu L.","family":"FUJII","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutomi","family":"KAMEI","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Nutrition, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"MIURA","sequence":"additional","affiliation":[{"name":"Laboratory of Nutritional Biochemistry, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1759","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Obsil T, Obsilova V. 2011. Structural basis for DNA recognition by FOXO proteins. Biochim Biophys Acta 1813: 1946-1953.","DOI":"10.1016\/j.bbamcr.2010.11.025"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kamei Y, Mizukami J, Miura S, Suzuki M, Takahashi N, Kawada T, Taniguchi T, Ezaki O. 2003. A forkhead transcription factor FKHR up-regulates lipoprotein lipase expression in skeletal muscle. FEBS Lett 536: 232-236.","DOI":"10.1016\/S0014-5793(03)00062-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ajima H, Kai Y, Fujimaki J, Akashi S, Morita A, Ezaki O, Kamei Y, Miura S. 2021. Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets. J Toxicol Sci 46: 11-24.","DOI":"10.2131\/jts.46.11"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H. 2011. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 13: 170-182.","DOI":"10.1016\/j.cmet.2011.01.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412.","DOI":"10.1016\/S0092-8674(04)00400-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sengupta A, Molkentin JD, Yutzey KE. 2009. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 284: 28319-28331.","DOI":"10.1074\/jbc.M109.024406"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yamazaki Y, Kamei Y, Sugita S, Akaike F, Kanai S, Miura S, Hirata Y, Troen BR, Kitamura T, Nishino I, Suganami T, Ezaki O, Ogawa Y. 2010. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle. Biochem J 427: 171-178.","DOI":"10.1042\/BJ20091346"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sanchez AM, Candau RB, Bernardi H. 2014. FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis. Cell Mol Life Sci 71: 1657-1671.","DOI":"10.1007\/s00018-013-1513-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Webb AE, Brunet A. 2014. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci 39: 159-169.","DOI":"10.1016\/j.tibs.2014.02.003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T, Matsuda J, Aburatani H, Nishino I, Ezaki O. 2004. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch\/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 279: 41114-41123.","DOI":"10.1074\/jbc.M400674200"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) O\u2019Neill BT, Bhardwaj G, Penniman CM, Krumpoch MT, Suarez Beltran PA, Klaus K, Poro K, Li M, Pan H, Dreyfuss JM, Nair KS, Kahn CR. 2019. FoxO transcription factors are critical regulators of diabetes-related muscle atrophy. Diabetes 68: 556-570.","DOI":"10.2337\/db18-0416"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Reed SA, Sandesara PB, Senf SM, Judge AR. 2012. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J 26: 987-1000.","DOI":"10.1096\/fj.11-189977"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kamei Y, Ohizumi H, Fujitani Y, Nemoto T, Tanaka T, Takahashi N, Kawada T, Miyoshi M, Ezaki O, Kakizuka A. 2003. PPARgamma coactivator 1beta\/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci USA 100: 12378-12383.","DOI":"10.1073\/pnas.2135217100"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hamaguchi H, Matsui TS, Deguchi S, Furuichi Y, Fujii NL, Manabe Y. 2022. Establishment of a system evaluating the contractile force of electrically stimulated myotubes from wrinkles formed on elastic substrate. Sci Rep 12: 13818.","DOI":"10.1038\/s41598-022-17548-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Perard-Viret J, Quteishat L, Alsalim R, Royer J, Dumas F. 2017. Cephalotaxus alkaloids. Alkaloids Chem Biol 78: 205-352.","DOI":"10.1016\/bs.alkal.2017.07.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Franco DP, de Biazi BI, Zanetti TA, Marques LA, de Lima L, Lepri SR, Mantovani MS. 2020. Apoptotic and cell cycle response to homoharringtonine and harringtonine in wild and mutant p53 hepatocarcinoma cells. Hum Exp Toxicol 39: 1405-1416.","DOI":"10.1177\/0960327120926257"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gerashchenko MV, Peterfi Z, Yim SH, Gladyshev VN. 2021. Translation elongation rate varies among organs and decreases with age. Nucleic Acids Res 49: e9.","DOI":"10.1093\/nar\/gkaa1103"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Brown AK, Webb AE. 2018. Regulation of FOXO factors in mammalian cells. Curr Top Dev Biol 127: 165-192.","DOI":"10.1016\/bs.ctdb.2017.10.006"},{"key":"19","unstructured":"19) Russo D, Michelutti A, Melli C, Damiani D, Michieli MG, Candoni A, Zhou DC, Marie JP, Zittoun R, Baccarani M. 1995. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 9: 513-516."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708.","DOI":"10.1126\/science.1065874"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Chung SW, Kim JY, Yoon JP, Suh DW, Yeo WJ, Lee YS. 2020. Atrogin1-induced loss of aquaporin 4 in myocytes leads to skeletal muscle atrophy. Sci Rep 10: 14189.","DOI":"10.1038\/s41598-020-71167-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wang H, Liu D, Cao P, Lecker S, Hu Z. 2010. Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes 59: 1879-1889.","DOI":"10.2337\/db10-0207"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sato T, Morita A, Watanabe Y, Naito Y, Kawaji H, Nakagawa T, Hamaguchi H, Manabe Y, Fujii NL, Ogo N, Asai A, Kamei Y, Miura S. 2025. Rebastinib inhibits FoxO1 activity and reduces dexamethasone-induced atrophy and its-related gene expression in cultured myotubes. J Physiol Sci 75: 100012.","DOI":"10.1016\/j.jphyss.2025.100012"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC. 2008. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 295: E785-797.","DOI":"10.1152\/ajpendo.00646.2007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Powell RG, Weisleder D, Smith CR Jr. 1972. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 61: 1227-1230.","DOI":"10.1002\/jps.2600610812"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Jiang TL, Liu RH, Salmon SE. 1983. Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells. Invest New Drugs 1: 21-25.","DOI":"10.1007\/BF00180188"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Takeda S, Yajima N, Kitazato K, Unemi N. 1982. Antitumor activities of harringtonine and homoharringtonine, cephalotaxus alkaloids which are active principles from plant by intraperitoneal and oral administration. J Pharmacobiodyn 5: 841-847.","DOI":"10.1248\/bpb1978.5.841"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kaur P, Thiruchelvan M, Lee RC, Chen H, Chen KC, Ng ML, Chu JJ. 2013. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother 57: 155-167.","DOI":"10.1128\/AAC.01467-12"},{"key":"29","unstructured":"29) Zhou DC, Zittoun R, Marie JP. 1995. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 82: 987-995."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Gurel G, Blaha G, Moore PB, Steitz TA. 2009. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 389: 146-156.","DOI":"10.1016\/j.jmb.2009.04.005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Zhao J, Zhai B, Gygi SP, Goldberg AL. 2015. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc Natl Acad Sci USA 112: 15790-15797.","DOI":"10.1073\/pnas.1521919112"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Fresno M, Jimenez A, Vazquez D. 1977. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 72: 323-330.","DOI":"10.1111\/j.1432-1033.1977.tb11256.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Wang F, Demir S, Gehringer F, Osswald CD, Seyfried F, Enzenmuller S, Eckhoff SM, Maier T, Holzmann K, Debatin KM, Wirth T, Meyer LH, Ushmorov A. 2018. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. Blood 131: 2929-2942.","DOI":"10.1182\/blood-2017-10-813576"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, Kostalova L, Mladonicka Pavlasova G, Filip D, Vecera J, Zeni PF, Oppelt J, Kahounova Z, Vichova R, Soucek K, Panovska A, Plevova K, Pospisilova S, Simkovic M, Vrbacky F, Lysak D, Fernandes SM, Davids MS, Maiques-Diaz A, Charalampopoulou S, Martin-Subero JI, Brown JR, Doubek M, Forconi F, Mayer J, Mraz M. 2024. FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Invest 134: e173770.","DOI":"10.1172\/JCI173770"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A. 2023. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death Dis 14: 642.","DOI":"10.1038\/s41419-023-06168-2"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY, Wang YY, Long J, Wu SF, Zhang YX, Wang S, Li SX, Yin T, Lu M, Xi XD, Li JM, Wang KK, Chen Z, Chen SJ. 2019. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-kappaB repressing factor. Proc Natl Acad Sci USA 116: 2220-2225.","DOI":"10.1073\/pnas.1818539116"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Li C, Dong L, Su R, Bi Y, Qing Y, Deng X, Zhou Y, Hu C, Yu M, Huang H, Jiang X, Li X, He X, Zou D, Shen C, Han L, Sun M, Skibbe J, Ferchen K, Qin X, Weng H, Huang H, Song C, Chen J, Jin J. 2020. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1\/TET1\/5hmC. Haematologica 105: 148-160.","DOI":"10.3324\/haematol.2018.208835"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Wang W, Cassidy J. 2003. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer 88: 624-629.","DOI":"10.1038\/sj.bjc.6600753"}],"container-title":["Journal of Nutritional Science and Vitaminology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnsv\/71\/3\/71_256\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:10:28Z","timestamp":1751688628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnsv\/71\/3\/71_256\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3177\/jnsv.71.256","relation":{},"ISSN":["0301-4800","1881-7742"],"issn-type":[{"type":"print","value":"0301-4800"},{"type":"electronic","value":"1881-7742"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}